B-Cell Malignancies
Showing 1 - 25 of >10,000
Relapsed/Refractory B-cell Malignancies Trial (AC676)
Not yet recruiting
- Relapsed/Refractory B-cell Malignancies
- (no location specified)
Mar 27, 2023
B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)
Recruiting
- B Cell Malignancies
- Universal CD19-specific CAR gene-engineered T cells
-
Beijing, Beijing, China
- +2 more
Aug 8, 2023
Relapsed/Refractory Aggressive B-Cell Malignancies Trial (ONCT-808, Bridging Therapy)
Not yet recruiting
- Relapsed/Refractory Aggressive B-Cell Malignancies
- ONCT-808
- Bridging Therapy
- (no location specified)
Jan 19, 2023
B-Cell Malignancies Trial (TT-01488 Tablets)
Not yet recruiting
- B-Cell Malignancies
- TT-01488 Tablets
- (no location specified)
Jan 4, 2023
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)
Not yet recruiting
- Non Hodgkin Lymphoma
- +5 more
- Pirtobrutinib
- LV20.19 CAR T cells
- (no location specified)
Aug 4, 2023
B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors Trial in Kunming (Anti-CD19 Autologous CAR-T Cell Infusion)
Recruiting
- B-Cell Leukemia
- +2 more
- Anti-CD19 Autologous CAR-T Cell Infusion
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Jul 9, 2023
Pediatric and Young Adult B-Cell Malignancies After Commercially
Not yet recruiting
- Lymphoid Leukemia
- Questionnaire for patients receiving therapy
-
Palo Alto, CaliforniaStanford University
May 9, 2023
Hematological Malignancies Trial in Tianjin (ICP-248)
Not yet recruiting
- Hematological Malignancies
-
Tianjin, Tianjin, ChinaHematology Hospital, Chinese Academy of Medical Sciences
Feb 13, 2023
CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,
Not yet recruiting
- CD19-positive Relapsed or Refractory B-cell Malignancies
- UTAA09 cells for infusion
- +2 more
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023
B-cell Malignancies Undergoing Treatment With Bruton Tyrosine
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +4 more
- Non-Interventional Study
-
Rochester, MinnesotaMayo Clinic in Rochester
Nov 22, 2023
R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,
Recruiting
- R/R CD19-Positive B-Cell Malignancies
- +2 more
- CNTY-101
- +2 more
-
Detroit, Michigan
- +1 more
Dec 21, 2022
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Anti-CD19 and anti-CD20 bicistronic CAR T- cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 10, 2023
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- +6 more
- (no location specified)
Apr 12, 2023
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)
Recruiting
- Follicular Lymphoma
- +4 more
- Obinutuzumab
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Fairway, Houston (SC291)
Recruiting
- Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
-
Fairway, Kansas
- +1 more
May 30, 2023
Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR
Not yet recruiting
- Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
- MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
-
Dresden, GermanyTechnische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023
Adult Relapsed/Refractory B-cell Hematologic Malignancies Trial in Beijing (CD19-CAR-NK)
Recruiting
- Adult Relapsed/Refractory B-cell Hematologic Malignancies
- CD19-CAR-NK
-
Beijing, Beijing, ChinaThe Fifth Medical Center of Chinese People's Liberation Army (PL
Dec 1, 2022
B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)
Recruiting
- B-cell Lymphoma
- +5 more
- Cyclophosphamide
- +3 more
-
Louisville, KentuckyNorton Cancer Institute
Jan 24, 2023
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell Trial in United Kingdom (ALETA-001)
Not yet recruiting
- Lymphoma, Non-Hodgkin
- +4 more
-
Birmingham, United Kingdom
- +5 more
Sep 18, 2023
B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy Trial (CTX112)
Not yet recruiting
- B-cell Lymphoma
- +7 more
- CTX112
- (no location specified)
Dec 12, 2022
Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- +5 more
- P-CD19CD20-ALLO1
- Rimiducid
-
La Jolla, California
- +7 more
Aug 25, 2023
NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia Trial (KUR-502)
Not yet recruiting
- NHL, Relapsed, Adult
- +3 more
- KUR-502
- (no location specified)
Aug 2, 2022
B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/79b T cells)
Recruiting
- B Cell Malignancies
- bi-4SCAR CD19/79b T cells
-
Shenzhen, Guangdong, ChinaShenzhen Geno-immune Medical Institute
Jun 28, 2022
DLBCL, Chronic Lymphocytic Leukemia, B Cell Malignancies Trial in Australia, United States (ABBV-525)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +3 more
-
Louisville, Kentucky
- +6 more
Nov 14, 2022
Lymphoma Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (PNEUMOVAX 23, Fluarix, FluLaval)
Recruiting
- Lymphoma
- PNEUMOVAX 23
- +9 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022